SNDX: Key phase II readouts and expanding maintenance therapy drive growth and pipeline momentum
Two commercial drugs are driving strong revenue growth, with recurring post-transplant maintenance therapy emerging as a key driver. Multiple pivotal and phase II readouts are expected in the next year, including for IPF and cGVHD, while new pipeline assets targeting NSCLC and myelofibrosis are adv…